What types of pathogens can Creative Biolabs' infectious animal models accommodate?

Creative Biolabs' infectious animal models can accommodate a broad spectrum of pathogens, including viral agents, fungal species, and worms. For pathogens not explicitly listed, proprietary model development services are available upon consultation.

How does Creative Biolabs achieve reproducibility in infectious disease animal models?

Strict standardization governs pathogen preparation, animal husbandry (SPF conditions), challenge protocols (dose-response validation), and endpoint analysis. All experimental participants have received professional training, and validated models undergo QA and QC during the experiment to ensure data authenticity and repeatability.

Does Creative Biolabs offer customized infectious model development?

Certainly. Creative Biolabs offers not only verified models but also provides custom model development and validation services, specifically tailored to meet your unique requirements.

What are the key advantages of choosing Creative Biolabs’ infectious model services?

Opting for Creative Biolabs' infectious model services presents several key benefits, including access to mature animal modeling experience, advanced equipment, and expert personnel. Our streamlined processes reduce procedural complexities, expediting research and development timelines and minimizing time and expenses.

What will you gain when Creative Biolabs completes the entire Pharmacodynamics infectious model R & D process?

Upon completion of the R&D process, the recipient will receive a comprehensive evaluation report encompassing tailored methodologies, professionally analyzed results, and accompanying raw data.

Infectious Disease Animal Modeling & Pharmacodynamics Services

Introduction

Infectious diseases continue to be a primary contributor to global mortality, causing over 13 million deaths annually and accounting for more than 25% of all human fatalities. Although there have been advances in worldwide prevention and control measures, the complete eradication of these diseases continues to be a daunting challenge. Creative Biolabs offers comprehensive model system, a wide spectrum of pathogen, validated models, reliable results and full-cycle infectious disease model services, offering customized animal models (including rodents, non-rodents, non-human primates, fruit flies, and zebrafish) and cellular models tailored to study viruses, bacteria, fungi, and parasites. Our advanced models facilitate the acceleration of drug R&D and the Investigational New Drug (IND).

Animal species used for infectious disease modeling (OA Literature) Fig. 1 Animal species of animal models for infectious diseases.^1,3

Available Infectious Disease Models

Creative Biolabs can facilitate a variety of pre-clinical R&D, including vaccines, chemical drugs, gene therapies, biological drugs, cell therapies and novel therapeutic approaches. Learn more about the existing well-characterized models of infectious diseases models for preclinical research by clicking on the links below:

Available Pathogens

Pathogen reservoirs utilized in our infectious disease models encompass

Classify		Pathogen type
Viral	Respirovirus	Influenza virus A/B/C, SARS-CoV-2, Respiratory syncytial virus (RSV), Adenovirus, Rhinovirus, Measles virus, Mumps virus, Varicella zoster virus
	Gastrointestinal tract viruses	HAV, HEV, Rotavirus, Norovirus
	Blood/STIs viruses	Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human immunodeficiency virus (HIV)-1/-2, Human papillomavirus (HPV, more than 100 types), Herpes simplex virus (HSV)-1/-2, Epstein-Barr virus
	Arbovirus	Dengue virus, Zika virus, Yellow fever virus, Japanese encephalitis virus
	Zoonotic viruses	Rabies virus, Hantavirus, Monkeypox virus, Ebola virus
Bacterial	Gram-positive	Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecalis, Bacillus anthracis), Clostridium tetani, Clostridium perfringens, etc.
	Gram-negative	Neisseria meningitidis, Neisseria gonorrhoeae, Haemophilus influenzae, Escherichia coli, Salmonella typhi, Shigella, Pseudomonas aeruginosa, Klebsiella pneumoniae, Helicobacter pylori, Brucella, Yersinia pestis, Legionella pneumophila, etc.
	Others	Mycobacterium tuberculosis, Mycobacterium leprae, Bordetella pertussis, Campylobacte, Treponema pallidum, Leptospira spp., Rickettsia spp., Rickettsia spp., etc.
Fungal	Yeast fungi	Candida albicans, Candida tropicalis, Cryptococcus neoformans, Penicillium marneffei
	Filamentous fungi	Aspergillus fumigatus, Aspergillus flavus, Mucor spp., Rhizopus spp., Sporothrix schenckii
	Skin fungi	Dermatophytes, Trichophyton spp., Microsporum spp., Epidermophyton spp.
	Deep fungi	Histoplasma capsulatum, Coccidioides immitis, Paracoccidioides brasiliensis, Blastomyces dermatitidis
Parasitic	Protozoon	Plasmodium spp., Toxoplasma gondii, Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis, Leishmania donovani, Trypanosoma brucei, Trypanosoma cruzi, etc.
	Fluke	Schistosoma japonicum, Schistosoma mansoni, Clonorchis sinensis, Paragonimus westermani
	Tapeworm	Taenia solium, Taenia saginata, Echinococcus granulosus
	Nematode	Ascaris lumbricoides, Ancylostoma duodenale, Necator americanus, Enterobius vermicularis, Trichuris trichiura, Wuchereria bancrofti, Brugia malayi

Measurements

Pharmacodynamic models are subjected to rigorous validation, employing multi-modal analytical platforms to ensure their accuracy and reliability.

Clinical Monitoring: Systematic evaluation of biometric parameters (coat and skin condition, body weights, organ indices), physiological status (respiratory function, mental status), behavioral metrics (locomotor activity, mental status), and survival outcomes.
Virological Profiling: Viral quantification via TCID50 assays, plaque assays, and antigen detection through ELISA/immunofluorescence.
Immune Response Mapping: Multiplex cytokine analysis across biological matrices, complemented by flow cytometric immunophenotyping.
Molecular Biology: Transcript-level verification through quantitative reverse transcription PCR (RT-PCR) and protein expression validation via immunoblotting.
Systemic Pathological Evaluation: Consolidated hematology, serum biochemistry, advanced histopathology, and micro-CT imaging.

Related Disease Models

Tumor Models

Neurological Disorder Models

Inflammation & Immunological Disease Models

Metabolic/Liver Disease Models

Urological System Disease Models

Digestive System Disease Models

Cardiovascular Disease Models

Respiratory Disease Models

Ocular Disease Models

Musculoskeletal Disease Models

Ear Disorder Models

Reproductive System Disease Models

Skin Disease Mode

Our Advantages

Comprehensive Service Chain: Our integrated service chain encompasses the entire drug development lifecycle, from target discovery and preclinical research through IND application support.
Multidisciplinary Team Composition: Our team consists of multidisciplinary experts who provide professional, customized, and precise research programs for infectious animal models, thereby expediting project advancement and reducing the new drug development cycle.
Data and Experience Accumulation: A continuously expanding database of standardized preclinical models and a comprehensive pathogen library. This extensive resource facilitates the rapid deployment of comparative approaches for various therapeutic programs.
One-stop Services: Multidisciplinary teams provide bespoke modeling strategies, leveraging expertise in virology, immunology, and translational medicine to satisfy IND requirements.

Work with Us

Inquiry Stage

Summarize the project requirements and fill in the information collection form.
Sign a CDA from both parties to further communicate information, such as targets.
Select an animal model, discuss experimental design, and determine assay parameters.
Project costing and project schedule forecasting.

Project Start

We provide a detailed project plan, including the required sample quantities, methods, and protocols.
Both parties confirm the project details and start the project.
Confirm the timeline of the project.

Project Progress

We provide periodic results and information on the animal's condition.
We will work together to make project adjustments as necessary.

Project Completion

We provide a comprehensive project report promptly.
We arrange transportation for the produced samples.
We provide a discussion of the project results and help to arrange the next steps.

After-Sales Support

Data storage and archiving.

Get in touch!

FAQs

Q. What types of pathogens can Creative Biolabs’ infectious animal models accommodate?

A: Creative Biolabs' infectious animal models can accommodate a broad spectrum of pathogens, including viral agents, fungal species, and worms. For pathogens not explicitly listed, proprietary model development services are available upon consultation.
Q. How does Creative Biolabs achieve reproducibility in infectious disease animal models?

A: Strict standardization governs pathogen preparation, animal husbandry (SPF conditions), challenge protocols (dose-response validation), and endpoint analysis. All experimental participants have received professional training, and we use validated models verified by QA and QC during the experiment to ensure data authenticity and experimental repeatability.
Q. Does Creative Biolabs offer customized infectious model development?

A: Certainly. Creative Biolabs not only offers verified models, but also provides custom model development and validation services, specifically tailored to meet your unique requirements.
Q: What are the key advantages of choosing Creative Biolabs’ infectious model services?

A: Opting for Creative Biolabs' infectious model services, as opposed to establishing in-house animal models, presents several key benefits:

Established Expertise: Access to mature animal modeling experience and specialized animal facilities.

Expert Personnel: Engagement with a team of experienced scientists.

Advanced Equipment: Utilization of cutting-edge experimental equipment.

Reduced Complexity: Streamlined processes minimize procedural complexities.

Our streamlined processes minimize procedural complexities, leading to a significant reduction in both time and expenses associated with personnel training. This ultimately expedites research and development timelines.
Q: What will you gain when Creative Biolabs completes the entire Pharmacodynamics infectious model R & D process?

A: Upon the completion of the research and development process by Creative Biolabs, the recipient will receive a comprehensive evaluation report. This report will encompass tailored methodologies, professionally analyzed results, and the accompanying raw data.

Published Data

Mouse Cholera Model: To evaluate the efficacy of combined oral and parenteral cholera vaccina. Fecal Bacterial Colonization indicate transient intestinal colonization by the vaccine strain (Fig. 16A), the combination group (oral and injectable) exhibited the highest vibriocidal antibody titers and OSP-Specific IgM Memory B Cell Responses (P < 0.05, Fig. 12B-C).

Picture of Cholera Model (OA Literature) Fig.2 The efficacy of combined oral and parenteral cholera vaccination.^2,3

References

Bi, Zhenfei, Hong Weiqi, Yang Jingyun, et al. Animal models for SARS-CoV-2 infection and pathology. MedComm 2.4 (2021): 548-568. https://doi.org/10.1002/mco2.98
Akter, Aklima, Meagan Kelly, Charles Richelle C, et al. Parenteral vaccination with a cholera conjugate vaccine boosts vibriocidal and anti-OSP responses in mice previously immunized with an oral cholera vaccine. The American Journal of Tropical Medicine and Hygiene 104.6 (2021): 2024. https://doi.org/10.4269/ajtmh.20-1511
Distributed under Open Access license CC BY 4.0, without modification.